Innovation & Biomarkers in Cancer Drug Developpement - IBCD 2018

IBCD 2018 will explore routes through the evolving scientific, methodological and regulatory environment. The combined efforts of the EORTC, NCI, EMA, and AACR with the involvement of FDA and PMDA and Health Technology Assessment specialists will result in a unique program. The 2018-edition will build upon the recommendations and action points decided upon at the IBCD2016-edition. Topics, which will be developed, will include items like Health Technology Assessment (HTA) of biomarker assays, comparative effectiveness research and the translation of findings of clinical trials into daily practice.